Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/09/17 | 1,286 | 1,354 | 1,286 | 1,340 | +60 | +4.7% | 69,700 |
2021/09/16 | 1,365 | 1,393 | 1,256 | 1,280 | -34 | -2.6% | 162,500 |
2021/09/15 | 1,338 | 1,351 | 1,309 | 1,314 | -29 | -2.2% | 50,900 |
2021/09/14 | 1,363 | 1,385 | 1,336 | 1,343 | -27 | -2% | 52,400 |
2021/09/13 | 1,364 | 1,381 | 1,355 | 1,370 | -11 | -0.8% | 38,400 |
2021/09/10 | 1,365 | 1,386 | 1,345 | 1,381 | +46 | +3.4% | 35,900 |
2021/09/09 | 1,358 | 1,393 | 1,335 | 1,335 | -25 | -1.8% | 35,800 |
2021/09/08 | 1,360 | 1,399 | 1,357 | 1,360 | -5 | -0.4% | 41,500 |
2021/09/07 | 1,382 | 1,419 | 1,360 | 1,365 | -4 | -0.3% | 66,600 |
2021/09/06 | 1,373 | 1,389 | 1,320 | 1,369 | +8 | +0.6% | 107,600 |
2021/09/03 | 1,396 | 1,415 | 1,354 | 1,361 | -37 | -2.6% | 117,500 |
2021/09/02 | 1,489 | 1,489 | 1,398 | 1,398 | -102 | -6.8% | 108,300 |
2021/09/01 | 1,428 | 1,509 | 1,420 | 1,500 | +58 | +4% | 103,300 |
2021/08/31 | 1,473 | 1,477 | 1,417 | 1,442 | -31 | -2.1% | 139,900 |
2021/08/30 | 1,510 | 1,512 | 1,469 | 1,473 | -37 | -2.5% | 66,100 |
2021/08/27 | 1,529 | 1,542 | 1,500 | 1,510 | -27 | -1.8% | 31,500 |
2021/08/26 | 1,527 | 1,550 | 1,509 | 1,537 | +31 | +2.1% | 24,200 |
2021/08/25 | 1,558 | 1,571 | 1,506 | 1,506 | -50 | -3.2% | 62,600 |
2021/08/24 | 1,515 | 1,585 | 1,515 | 1,556 | +71 | +4.8% | 92,000 |
2021/08/23 | 1,431 | 1,524 | 1,430 | 1,485 | +46 | +3.2% | 59,100 |
2021/08/20 | 1,460 | 1,508 | 1,427 | 1,439 | -19 | -1.3% | 57,600 |
2021/08/19 | 1,499 | 1,572 | 1,458 | 1,458 | -41 | -2.7% | 94,100 |
2021/08/18 | 1,436 | 1,508 | 1,430 | 1,499 | +49 | +3.4% | 64,000 |
2021/08/17 | 1,449 | 1,504 | 1,430 | 1,450 | +8 | +0.6% | 65,400 |
2021/08/16 | 1,482 | 1,485 | 1,424 | 1,442 | -61 | -4.1% | 90,300 |
2021/08/13 | 1,500 | 1,525 | 1,452 | 1,503 | -4 | -0.3% | 75,900 |
2021/08/12 | 1,540 | 1,549 | 1,492 | 1,507 | -54 | -3.5% | 68,900 |
2021/08/11 | 1,557 | 1,585 | 1,540 | 1,561 | +5 | +0.3% | 32,500 |
2021/08/10 | 1,496 | 1,568 | 1,493 | 1,556 | +20 | +1.3% | 62,800 |
2021/08/06 | 1,543 | 1,560 | 1,506 | 1,536 | +17 | +1.1% | 66,300 |
2021/08/05 | 1,527 | 1,587 | 1,515 | 1,519 | -8 | -0.5% | 95,600 |
2021/08/04 | 1,599 | 1,600 | 1,512 | 1,527 | -81 | -5% | 174,100 |
2021/08/03 | 1,649 | 1,673 | 1,595 | 1,608 | -24 | -1.5% | 58,200 |
2021/08/02 | 1,655 | 1,655 | 1,547 | 1,632 | -51 | -3% | 149,500 |
2021/07/30 | 1,714 | 1,715 | 1,624 | 1,683 | -31 | -1.8% | 119,000 |
2021/07/29 | 1,694 | 1,746 | 1,678 | 1,714 | +26 | +1.5% | 90,800 |
2021/07/28 | 1,744 | 1,757 | 1,662 | 1,688 | -95 | -5.3% | 175,100 |
2021/07/27 | 1,847 | 1,859 | 1,781 | 1,783 | -81 | -4.3% | 118,300 |
2021/07/26 | 1,921 | 1,928 | 1,842 | 1,864 | -22 | -1.2% | 104,000 |
2021/07/21 | 1,821 | 1,911 | 1,789 | 1,886 | +79 | +4.4% | 170,300 |
2021/07/20 | 1,811 | 1,885 | 1,795 | 1,807 | -22 | -1.2% | 142,300 |
2021/07/19 | 1,790 | 1,903 | 1,774 | 1,829 | +67 | +3.8% | 175,100 |
2021/07/16 | 1,719 | 1,789 | 1,691 | 1,762 | +45 | +2.6% | 125,100 |
2021/07/15 | 1,735 | 1,736 | 1,690 | 1,717 | -15 | -0.9% | 78,200 |
2021/07/14 | 1,717 | 1,749 | 1,705 | 1,732 | +35 | +2.1% | 59,200 |
2021/07/13 | 1,695 | 1,739 | 1,680 | 1,697 | +2 | +0.1% | 79,500 |
2021/07/12 | 1,698 | 1,725 | 1,655 | 1,695 | +18 | +1.1% | 113,300 |
2021/07/09 | 1,570 | 1,682 | 1,564 | 1,677 | +98 | +6.2% | 172,700 |
2021/07/08 | 1,605 | 1,631 | 1,550 | 1,579 | -46 | -2.8% | 210,700 |
2021/07/07 | 1,578 | 1,659 | 1,575 | 1,625 | +15 | +0.9% | 159,400 |
651~
700
件表示中 / 1363件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 58,800円 | - | - | 0.00% | - | 3.93倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
カイノス | 114,800円 | +6.8% | -13.8% | 2.79% | 8.80倍 | 0.77倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
キッズバイオ | 13,000円 | - | - | 0.00% | - | 7.57倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞(SHED)用いた再生医療に力 |
ソレイジア | 2,600円 | +102.6% | - | 0.00% | - | 2.52倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
免疫生物 | 50,300円 | +13.4% | -4.0% | 0.00% | 40.73倍 | 3.70倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム